PharmaTelevision teams up with EBD Group to offer Television Interview and Media Training

NewsGuard 100/100 Score
Oct 15 2009

PharmaTelevision(R), the authoritative channel for the pharmaceutical, biotechnology and related industries, today announced that it is teaming up with the EBD Group to offer delegates at BIO-Europe a Television Interview and Media Training.

Dr Fintan Walton, CEO of PharmaVentures - the company behind PharmaTelevision - said, "Standing out and attaining share of voice is becoming increasingly difficult in the crowded world of biopharma partnering. Effective communication that makes an impact is critical for attracting partners and winning deals. That is why we have devised this unique package for BIO-Europe delegates."

Dr Walton continues, "By offering media training, we are helping to make our interviewees excellent communicators through the medium of television."

Source:

PharmaTelevision

Posted in: Miscellaneous News

Tags: ,

Comments (0)

Suggested Reading

Milestone in diabetes treatment: Transgenic cow produces human insulin in milk
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
RedShiftBio Welcomes Sebastian Arevalo as New Sales Leader
Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy
New study to test novel psychedelic compound as potential treatment for alcohol use disorder
From farm to pharmacy: Transgenic cow milk as a new source of human insulin
Study highlights global fertility decline and its implications for the future
New protein-based micromaterials developed for targeted cancer therapy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema